ALA arovella therapeutics limited

A new study has been published in the prestigious nature.com...

  1. 440 Posts.
    lightbulb Created with Sketch. 115

    A new study has been published in the prestigious nature.com website, completed by a whole range of scientists, but more importantly looks to be somewhat led by Gianpietro Dotti, who sits on our scientific advisory board. I will try summarise the article below, but is a very interesting and promising read and demonstrates the potential that iNKT cell therapy will far superior in the treatment of solid tumours vs CAR-T treament.

    Abstract:
    "Human natural killer T (NKT) cells have been proposed as a promising cell platform for chimeric antigen receptor (CAR) therapy in solid tumors. Here we generated murine CAR-NKT cells and compared them with CAR-T cells in immune-competent mice. Both CAR-NKT cells and CAR-T cells showed similar antitumor effects in vitro, but CAR-NKT cells showed superior antitumor activity in vivo via CD1d-dependent immune responses in the tumor microenvironment. Specifically, we show that CAR-NKT cells eliminate CD1d-expressing M2-like macrophages. In addition, CAR-NKT cells promote epitope spreading and activation of endogenous T cell responses against tumor-associated neoantigens. Finally, we observed that CAR-NKT cells can co-express PD1 and TIM3 and show an exhaustion phenotype in a model of high tumor burden. PD1 blockade as well as vaccination augmented the antitumor activity of CAR-NKT cells. In summary, our results demonstrate the multimodal function of CAR-NKT cells in solid tumors, further supporting the rationale for developing CAR-NKT therapies in the clinic

    Results:
    CAR-NKT cells target tumour cells in vitro
    "Collectively, these data show that muribe CAR-NKT cells can target tumour cells via CAR expression"
    CAR-NKT cells have superior anittumour activity to CAR-T cells in vivo

    "Collectively, these data show that CAR-NKT cells control tumour growth more effectively than CAR-T cells in vivo"
    CAR-NKT cells reprogram the TME and reduce M2-like macrophages in a CD1d-dependent manner"Overall, these data indicate that CAR-NKT cells mediate superior antitumor functionality compared with CAR-T cells and that this activity is mediated at least in part by the selective CD1d-dependent reduction of M2-like macrophages, while CD1d low-expressing M1-like macrophages are spared"
    CAR-NKT cells promote endogenous T Cell responses by activating DCs"Overall, these data demonstrate that PD1 blockade and vaccination further enhance the antitumor efficacy of CAR-NKT cells"

    Discussion:
    "In summary, our data show that CAR-NKT cells possess the unique ability to target both tumour cells and immunosuppressive M2-like macrophages. In addition, we also demonstrated that CAR-NKT cells can promote endogenous T cell responces to neoantigens in solid tumours by mediating CD1d-dependant activation of DCs. Finally, PD1 blockade and vaccination enhance CAR-NKT antitumor activity. Collectively, our results demonstrate the multimodal action of CAR-NKT cells in solid tumours, further supporting their exploration in clinical studies"


    article: https://www.nature.com/articles/s43018-024-00830-0
    Summary from Matthew Baker (Blue Ocean Equities): https://www.linkedin.com/feed/update/urn:li:activity:7251049572712505346/

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
10.5¢
Change
0.005(5.00%)
Mkt cap ! $124.8M
Open High Low Value Volume
10.0¢ 10.5¢ 10.0¢ $21.83K 212.0K

Buyers (Bids)

No. Vol. Price($)
12 443503 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 424264 6
View Market Depth
Last trade - 16.10pm 08/08/2025 (20 minute delay) ?
ALA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.